Drugs News and Research

RSS

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Ahmad M. Khalil, PhD, knew the odds were against him -- as in thousands upon thousands to one. Yet he and his team never wavered from their quest to identify the parts of the body responsible for revving up one of the most aggressive forms of breast cancer, HER2+. This month in Breast Cancer Research and Treatment, Khalil and his colleagues at Case Western Reserve University proved the power of persistence; from a pool of more than 30,000 possibilities, they found 38 genes and molecules that most likely trigger HER2+ cancer cells to spread.

25 Apr 2015

New study shows 'alarming rise' in costs of MS drugs over last 20 years

A new study shows an "alarming rise" over the last 20 years in the costs of drugs used to slow the progression of multiple sclerosis or reduce the frequency of attacks, according to a study led by researchers at Oregon Health & Science University and Oregon State University.

25 Apr 2015

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA).

25 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Asthma breakthrough: potential cause and corrective treatment are identified

A paper published yesterday in Science Translational Medicine reports that the root cause of asthma has been found and a potential treatment to reverse all symptoms has been proposed...

24 Apr 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Common tapeworm drug effectively treats MRSA superbugs in lab

A new study provides evidence from lab experiments that a drug already used in people to fight tapeworms might also prove effective against strains of the superbug MRSA, which kills thousands of people a year in the United States.

24 Apr 2015

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

A group of leading scientists has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is spent on developing new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases.

24 Apr 2015

New method offers quick spectral analysis of blood and melanin contents in skin sites

Many factors can change skin pigmentation, including aging, exposure to UV light, certain drugs, as well as certain diseases. A simple technique for measuring skin pigmentation could be a helpful tool for research and diagnostics. The same goes for measuring the skin blood content.

24 Apr 2015

Recommended alcoholic hepatitis treatments fail to increase patients' survival

The main drugs used to treat alcoholic hepatitis are not effective at increasing patients' survival, a major study has found. In a trial of over 1,000 patients, prednisolone and pentoxifylline, treatments recommended in international guidelines, did not achieve a statistically significant reduction in mortality after 28 days, 90 days or a year.

24 Apr 2015

Cardiff scientists make breakthrough asthma discovery

Cardiff University scientists have for the first time identified the potential root cause of asthma and an existing drug that offers a new treatment.

24 Apr 2015

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO is calling on the global health community to urgently address significant gaps in the prevention, diagnosis and treatment of malaria. Despite dramatic declines in malaria cases and deaths since 2000, more than half a million lives are still lost to this preventable disease each year.

23 Apr 2015

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Thanks to the generosity of a philanthropy dedicated to children's issues, renowned Down syndrome researcher Alberto Costa, MD, PhD, has taken yet another step toward making Northeast Ohio the nation's leader in exploring potential treatments of the genetic condition that affects 400,000 people in the U.S.

23 Apr 2015

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far.

23 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

Children exposed to adverse childhood experience more likely to develop asthma

Robyn Wing, M.D., an emergency medicine physician at Hasbro Children's Hospital, recently led a study that found children who were exposed to an adverse childhood experience (ACE) were 28 percent more likely to develop asthma.

23 Apr 2015

Several drugs could lead to new MS treatment options

New research published this week in Nature has found several drugs could lead to new treatment options for multiple sclerosis (MS), including two drugs that effectively treat MS at the source, in vivo. When administered at the peak of disease, these two drugs showed a striking reversal of disease severity.

23 Apr 2015

Cardiff scientists identify potential root cause of asthma and highlight new treatment option

Cardiff University scientists have for the first time identified the potential root cause of asthma and an existing drug that offers a new treatment.

23 Apr 2015

ADHD children at risk for eating disorder

Children with attention deficit hyperactivity disorder, or ADHD, are significantly more likely to have an eating disorder — a loss of control eating syndrome (LOC-ES) — akin to binge eating, a condition more generally diagnosed only in adults, according to results of a new Johns Hopkins Children's Center study.

23 Apr 2015

Drugs News and Research

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

New study shows 'alarming rise' in costs of MS drugs over last 20 years

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Asthma breakthrough: potential cause and corrective treatment are identified

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Common tapeworm drug effectively treats MRSA superbugs in lab

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

New method offers quick spectral analysis of blood and melanin contents in skin sites

Recommended alcoholic hepatitis treatments fail to increase patients' survival

Cardiff scientists make breakthrough asthma discovery

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

Case Western Reserve and MIT receive $1.7 million to explore potential treatments for Down syndrome

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Children exposed to adverse childhood experience more likely to develop asthma

Several drugs could lead to new MS treatment options

Cardiff scientists identify potential root cause of asthma and highlight new treatment option

ADHD children at risk for eating disorder

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News